$64.68 0.08 (+0.12%)
2/13/2012 2:15 PM

Johnson & Johnson (NYSE:JNJ)

CAPS Rating: 5 out of 5

A vast and diverse health care giant, Johnson & Johnson strives to help people get well through its consumer products, pharmaceuticals, and medical devices.

Results 1 - 20 of 2167 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar TMFDowCalls (34.31) Submitted: 2/13/2012 10:13:51 AM : Outperform Start Price: $65.16 JNJ Score: -1.58

Here's the video pitch:

http://www.fool.com/investing/general/2012/02/13/the-5-year-outlook-for-this-dow-stock-johnson-.aspx

Recs

0
Member Avatar badducky (31.20) Submitted: 2/3/2012 1:47:20 PM : Outperform Start Price: $65.61 JNJ Score: -2.11

Such a diverse range of vital consumer goods, with numerous household names. What a great company to own!

Recs

0
Member Avatar DRNGTREES (< 20) Submitted: 1/18/2012 4:31:21 PM : Outperform Start Price: $65.16 JNJ Score: -3.85

GOOD ONE

Recs

0
Member Avatar baselineace (51.48) Submitted: 1/15/2012 4:34:32 PM : Outperform Start Price: $65.38 JNJ Score: -9.46

Safe haven play.

Recs

0
Member Avatar rpgizzle (57.57) Submitted: 1/5/2012 10:19:23 PM : Outperform Start Price: $64.41 JNJ Score: -2.05

Everyone knows about the dividend, the moat, the stability, the margin.

For some reason nobody is talking about Rivaroxaban. Its a huge drug. It'll help them with their growth and margins.

Recs

0
Member Avatar Danpines (45.92) Submitted: 1/4/2012 5:54:58 PM : Underperform Start Price: $65.49 JNJ Score: +6.98

This company has product recalls every month. Their market share is going south. Well run companies do not have recall problems. This is not a well run company and the market will price that in the share price over the next 24 to 48 months.

Recs

0
Member Avatar TMFMT (61.44) Submitted: 1/3/2012 2:52:24 PM : Outperform Start Price: $65.81 JNJ Score: -9.21

3 companies that give back to shareholders,

http://www.fool.com/investing/general/2011/12/29/3-companies-that-give-back-to-shareholders.aspx?source=isesitlnk0000001&mrr=1.00

Recs

0
Member Avatar OrangeCaptain (< 20) Submitted: 12/30/2011 4:15:08 PM : Outperform Start Price: $65.59 JNJ Score: -7.29

They make half of the stuff you have in your household. They have solid management. Brand loyalty. Trusted name. Win.

Recs

0
Member Avatar cothron88 (61.70) Submitted: 12/27/2011 9:38:21 PM : Outperform Start Price: $62.95 JNJ Score: -3.12

They make a variety of products that people can't live without. They aren't recession proof, but they are strongly recession resistant. They pay a solid dividend and have slow but continuous growth

Recs

0
Member Avatar NHWeston (75.82) Submitted: 12/24/2011 5:22:03 PM : Outperform Start Price: $65.99 JNJ Score: -9.22

Looking into 2012, JNJ is picking up a lot of endorsements from money and financial publications, making various "Top Ten Lists."

Recs

0
Member Avatar guinness4life (34.23) Submitted: 12/21/2011 6:26:10 PM : Outperform Start Price: $65.06 JNJ Score: -9.15

Pharma. Good Div. Nice value metrics. Long until death.

Recs

0
Member Avatar szalay99 (< 20) Submitted: 12/7/2011 6:24:31 PM : Outperform Start Price: $64.14 JNJ Score: -6.63

Great Franchise. Solid Dividends

Recs

0
Member Avatar 1stMartian (26.94) Submitted: 12/4/2011 11:49:25 AM : Outperform Start Price: $64.10 JNJ Score: -5.77

Yield, balance sheet, ROI, cash flow.

Recs

1
Member Avatar mtinvest (90.02) Submitted: 12/2/2011 6:22:05 PM : Outperform Start Price: $61.29 JNJ Score: -6.37

Buffett has been selling, while he should be buying. I don't quite understand it, because he doesn't need the cash.

Recs

1
Member Avatar ndirish15 (47.63) Submitted: 11/29/2011 4:21:47 PM : Outperform Start Price: $63.92 JNJ Score: -8.38

In a slower economy, JNJ has the lockdown on inelastic goods (medical devices), while in a more prosperous environment it has a leg up on competition in terms of R&D output and acquisition potential. Also has a solid dividend and decent PE at the moment.

Recs

0
Member Avatar tbonci (65.60) Submitted: 11/28/2011 11:28:26 AM : Outperform Start Price: $62.24 JNJ Score: -8.80

Everyone knows Johnson & Johnson. They are the big dog in pharma, and the household name gives them a large moat in their consumer segment.

This company can withstand the test of time and market volatility. It has above average returns, and is priced cheaply. This is a great entry point into a great long term stock holding.

Recs

0
Member Avatar hblyth1 (32.02) Submitted: 11/16/2011 1:08:38 PM : Outperform Start Price: $64.34 JNJ Score: -7.17

Back to basics again.

Recs

0
Member Avatar HGMBH (57.09) Submitted: 11/14/2011 10:15:20 PM : Outperform Start Price: $64.37 JNJ Score: -7.62

One of my faves.

Recs

0
Member Avatar everycentcounts (59.44) Submitted: 11/12/2011 8:13:25 PM : Outperform Start Price: $64.37 JNJ Score: -6.74

Betting on JNJ value long term. Have read good things about this company that should see it grow well into the future.

Recs

1
Member Avatar BinyaminK (< 20) Submitted: 11/9/2011 1:47:16 PM : Outperform Start Price: $62.96 JNJ Score: -6.28

This is a "Giant Tortoise Stock." Like a giant tortoise, It may be big and slow, but it has a hard shell (economic moat), can swim far (enter into new and emerging markets and industries), and live long.

Featured Broker Partners


Advertisement